AVITA Medical Announces Positive Interim Results from Cohealyx® Study

Accelerated Time to Skin Grafting Demonstrated in Wound Healing Study

Apr. 14, 2026 at 12:07pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the intricate internal structure of a human skin graft, with a delicate network of tissues and vessels glowing against a dark background, conceptually representing the potential of advanced wound care solutions to enable rapid healing.Innovative dermal matrix technology aims to accelerate the skin grafting process, a critical step in treating severe wounds.New Orleans Today

AVITA Medical, a leading therapeutic acute wound care company, announced positive interim results from its Cohealyx-I multi-center study. The results showed a reduction of nearly 20 days in mean time to skin grafting (13.6 days vs 33.2 days benchmark) for patients with full-thickness wounds, with statistical superiority versus a literature-derived benchmark. The interim analysis of 40 patients also demonstrated a median time to grafting of 11 days, with grafting achieved as early as 5 days.

Why it matters

Preparing the wound bed efficiently is a key challenge in managing full-thickness wounds. These interim results indicate that Cohealyx, AVITA Medical's collagen-based dermal matrix, supports vascularization and enables earlier grafting, which is central to improving patient outcomes in the treatment of acute wounds.

The details

The interim analysis showed that 25% of patients were grafted within 7 days, and 72% were grafted within 14 days. Investigators reported 90% satisfaction at the time of grafting, including among predominantly first-time users, supporting consistent performance and potential for broader adoption in clinical practice. The data will be presented at an AVITA Medical symposium during the American Burn Association Annual Meeting.

  • The interim analysis was conducted on 40 patients.
  • The full dataset from the Cohealyx-I study is expected in 2026.

The players

AVITA Medical, Inc.

A leading therapeutic acute wound care company delivering transformative solutions, including the RECELL® and Cohealyx® products.

Derek Bell, MD

Professor of Plastic Surgery and Kessler Burn Director at the University of Rochester Medical Center.

Jonathan E. Schoen, MD, MPH, FACS, FABA

Medical Director of the UMCNO Verified Burn Center and Associate Professor of Clinical Surgery at the LSUHSC School of Medicine in New Orleans.

Cary Vance

Interim Chief Executive Officer of AVITA Medical.

Lourdes Castañón, MD, FACS

University of Arizona.

Got photos? Submit your photos here. ›

What they’re saying

“Preparing the wound bed efficiently remains one of the key challenges in managing full-thickness wounds. These interim results show that Cohealyx supports vascularization and enables earlier grafting, which is central to improving patient outcomes. Importantly, these results were achieved across a myriad of diverse and complex wounds.”

— Derek Bell, MD, Professor of Plastic Surgery and Kessler Burn Director, University of Rochester Medical Center

“This data strengthens our belief that Cohealyx can set a new benchmark in wound bed preparation. The meaningful reduction in time to grafting and high investigator satisfaction highlight its potential as a differentiated solution with the ability to drive broader adoption as we work to improve each stage of the wound healing pathway.”

— Cary Vance, Interim Chief Executive Officer of AVITA Medical

What’s next

AVITA Medical will host a KOL webinar featuring Dr. Bell and Dr. Castañón to review the data and case studies on Thursday, April 16, 2026, at 4:30 p.m. Eastern Time.

The takeaway

These positive interim results from the Cohealyx-I study demonstrate the potential for AVITA Medical's collagen-based dermal matrix to significantly accelerate the time to skin grafting, a critical step in the wound healing process. The high investigator satisfaction and consistent performance across diverse wound types suggest Cohealyx could become a differentiated solution to improve patient outcomes in the treatment of acute wounds.